Predict your next investment

Venture Capital
bvflp.com

See what CB Insights has to offer

Investments

98

Portfolio Exits

43

Partners & Customers

1

About BVF Partners

BVF Partners is a private investment partnership specializing in fundamentally-driven public biotechnology investments.

BVF Partners Headquarter Location

One Sansome Street 30th Floor

San Francisco, California, 94104,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BVF Partners News

Elektrofi Raises $40 Million Financing to Establish GMP Manufacturing Capabilities for Upcoming Clinical Studies and Expand Development Pipeline

Jun 13, 2022

The Series B financing was led by Marshall Wace and BVF Partners with participation from Janus Henderson and Logos Capital New funding will also support Elektrofi’s goals to expand pipeline, increase headcount, and advance internal R&D June 13, 2022 08:00 AM Eastern Daylight Time BOSTON--( BUSINESS WIRE )--Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced the completion of a $40 million Series B financing round. A portion of the proceeds will be used to establish a centralized GMP manufacturing line in support of multiple upcoming clinical trials. The company will also plan to double headcount over the next 12-18 months to accelerate development across a growing pipeline of licensed programs with leading pharma and biotech. Elektrofi’s breakthrough formulation platform addresses the long-standing and unmet need for stabilized, highly concentrated biologics. Based on a proprietary microparticle technology, the platform enables patient-friendly small-volume injections for monoclonal antibodies, therapeutic proteins, and other large molecule drugs that are of growing importance to human health. As the leading option for administration of high dose products with convenient prefilled syringes, pen injectors, and autoinjectors, it promises to drive significant positive change for patients across a wide variety of disease areas and indications. The financing was led by Marshall Wace and BVF Partners, with participation from Janus Henderson Investors and Logos Capital. “This financing sets the stage for advancement of multiple lead programs to human trials, clinical validation of Elektrofi’s high concentration technology, and pipeline expansion in response to significant inbound platform interest,” said Chase Coffman, CEO and Co-founder, Elektrofi. “We view this as a foundational step on our journey to making a meaningful difference for patients and their loved ones.” “We believe Elektrofi is establishing a transformational tool for the delivery of therapeutic proteins. We are pleased to partner with and support the next phase of the Company’s growth,” said Mark Lampert, CEO of BVF Partners. “Elektrofi has attracted notable partners and talent in biopharmaceutical development. We are proud to support the company’s mission to improve medication delivery and access for patients,” said Andrew Goldberg, MD, Managing Director at Marshall Wace. BTIG, LLC acted as exclusive placement agent for the offering. About Elektrofi Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company is shaping the future of biologics delivery. Visit www.elektrofi.com for more information. Contacts

BVF Partners Investments

98 Investments

BVF Partners has made 98 investments. Their latest investment was in Elektrofi as part of their Series B on June 6, 2022.

CBI Logo

BVF Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/13/2022

Series B

Elektrofi

$40M

Yes

5

3/29/2022

Series B

Dren Bio

$65M

No

1

2/23/2022

Series B

Plexium

$102M

Yes

9

2/16/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/9/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/13/2022

3/29/2022

2/23/2022

2/16/2022

2/9/2022

Round

Series B

Series B

Series B

Series B

Series C

Company

Elektrofi

Dren Bio

Plexium

Subscribe to see more

Subscribe to see more

Amount

$40M

$65M

$102M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

1

9

10

10

BVF Partners Portfolio Exits

43 Portfolio Exits

BVF Partners has 43 portfolio exits. Their latest portfolio exit was New Amsterdam Pharma on July 25, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/25/2022

Acq - Pending

$99M

1

4/29/2022

IPO

$99M

Public

5

3/25/2022

IPO

$99M

Public

12

1/7/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/8/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/25/2022

4/29/2022

3/25/2022

1/7/2022

10/8/2021

Exit

Acq - Pending

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

5

12

10

10

BVF Partners Partners & Customers

1 Partners and customers

BVF Partners has 1 strategic partners and customers. BVF Partners recently partnered with Ligand Pharmaceuticals on May 5, 2010.

Date

Type

Business Partner

Country

News Snippet

Sources

5/21/2010

Partner

United States

Download this Press Release (). Ligand - Ligand Acquired Milestone and Royalty Interest in AstraZeneca IL-9 Program for Asthma

As part of this transaction and a result of BVF 's contributions , Ligand Pharmaceuticals Incorporated entered into a separate agreement with BVF and certain of its affiliates , whereby BVF and Ligand Pharmaceuticals Incorporated will share the purchase price and any proceeds from the deal equally .

1

Date

5/21/2010

Type

Partner

Business Partner

Country

United States

News Snippet

Download this Press Release (). Ligand - Ligand Acquired Milestone and Royalty Interest in AstraZeneca IL-9 Program for Asthma

As part of this transaction and a result of BVF 's contributions , Ligand Pharmaceuticals Incorporated entered into a separate agreement with BVF and certain of its affiliates , whereby BVF and Ligand Pharmaceuticals Incorporated will share the purchase price and any proceeds from the deal equally .

Sources

1

BVF Partners Team

3 Team Members

BVF Partners has 3 team members, including current Managing Director, Kanishka Pothula.

Name

Work History

Title

Status

Mark Lampert

Founder

Current

Kanishka Pothula

Managing Director

Current

Spike Loy

Managing Director

Former

Name

Mark Lampert

Kanishka Pothula

Spike Loy

Work History

Title

Founder

Managing Director

Managing Director

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.